In Vectura Limited v. Glaxosmithkline LLC, [2020-1054] (November 19, 2020), the Federal Circuit affirmed the district court determination that U.S. Patent No. 8,303,991 directed to the production of “composite active particles” for use in pulmonary administration was not invalid and … Continue reading Apparatus Claims Sometimes Incorporate Process Limitations, but Not this Time